Inhibrx Biosciences (INBX)
Develops biologic drug candidates led by ozekibart and INBRX-106.
$101.49
vs last close−9.18 (−8.30%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 97.01% | 14.28M shares | |
|---|---|---|---|
| 178 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 15.45% | 2.27M shares | |
| 5 holders · as of Sep 17, 2026 | |||
| Adds to | 112.46% | ||
14.72M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 112.46%; nothing is left for Other.
13F, as of Jun 30, 2026
178 holders · 14.28M shares · 53 new positions · 110 increased · 41 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Morgan Stanley | 1.31M | 8.89% | +45.0K | Aug 13, 2026 |
| Perceptive Advisors LLC | 1.30M | 8.82% | −144.9K | Aug 14, 2026 |
| Sanofi | 1.16M | 7.87% | 0 | Jul 28, 2026 |
| Viking Global Investors LP | 1.12M | 7.64% | −313.8K | Aug 14, 2026 |
| Hightower Advisors, LLC | 870.6K | 5.92% | +351 | Aug 5, 2026 |
| Bank of America Corp /DE/ | 841.1K | 5.72% | +808.5K | Aug 14, 2026 |
| BlackRock, Inc. | 826.0K | 5.61% | +27.1K | Aug 7, 2026 |
| Schonfeld Strategic Advisors LLC | 697.6K | 4.74% | +442.8K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Perceptive Advisors LLC | 9.99% | 1.46M | 13G | May 15, 2026 |
| Viking Global Investors LP | 9.99% | 1.46M | 13G | May 15, 2026 |
| Perceptive Life Sciences Master Fund, Ltd.incl. Joseph Edelman, Perceptive Advisors LLC | 9.90% | 1.49M | 13G | Nov 14, 2024 |
| Morgan Stanley | 7.90% | 1.16M | 13G | Feb 11, 2026 |
| Jon Faiz Kayyemincl. The Jon F. Kayyem and Paige Gates-Kayyem Family Trust | 7.90% | 1.15M | 13D | Feb 26, 2025 |
| Mark Lappe | 6.40% | 925.4K | 13D | Feb 26, 2025 |
| Bank of America Corp /DE/ | 5.90% | 857.3K | 13G | Aug 3, 2026 |
| Schonfeld Strategic Advisors LLC | 5.33% | 781.7K | 13G | Aug 14, 2026 |
| BlackRock, Inc. | 5.30% | 768.1K | 13G | Jan 21, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 16, 2026 | Jon Faiz Kayyemdirector | Purchase | 5,000 | $100.00 | 429,360 |
| Sep 15, 2026 | Kimberly Manharddirector | Sale | 500 | $105.05 | 7,500 |
| Sep 14, 2026 | Kimberly Manharddirector | Sale | 500 | $110.26 | 8,000 |
| Sep 11, 2026 | Kimberly Manharddirector | Sale | 500 | $111.78 | 8,500 |
| Sep 9, 2026 | Kimberly Manharddirector | Sale | 500 | $115.80 | 9,000 |
| Sep 8, 2026 | Kimberly Manharddirector | Sale | 500 | $115.14 | 9,500 |
| Sep 8, 2026 | Jon Faiz Kayyemdirector | Purchase | 5,000 | $113.52 | 424,360 |
| Sep 8, 2026 | Douglas Forsythdirector | Purchase | 2,500 | $114.65 | 227,064 |
| Sep 8, 2026 | Mark Lappedirector, officer: Chief Executive Officer | Purchase · 6 lots | 25,000 | $105.82 | 730,548 |
| Oct 7, 2025 | Viking Global Investors LP10 percent owner | Sale · 3 lots | 350,000 | $32.25 | 67,018 |
House and Senate disclosures
Not reported.